Metformina Pharmconsul (Metformin Hydrochloride)

Metformin lowers blood glucose by inhibiting hepatic gluconeogenesis, reducing intestinal glucose absorption, and increasing peripheral insulin sensitivity. These actions are largely mediated through activation of AMP‑activated protein kinase (AMPK), which regulates metabolic pathways involved in glucose production and utilization.

The appropriate dose of Metformina Pharmconsul is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Dosage adjustments are made according to the prescriber’s judgment and local guidelines.

Safety of metformin in pregnancy or lactation is not fully established. It should only be used when the potential benefits to the mother outweigh any possible risks to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformina Pharmconsul (metformin) belongs to the biguanide class and is often first‑line therapy for type 2 diabetes because of its efficacy, low risk of hypoglycaemia and favourable impact on weight. Compared with sulfonylureas or insulin, it does not cause weight gain and has a well‑documented safety profile when used appropriately.

Metformina Pharmconsul should be stored at ambient temperature, below 25 °C, in the original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain its stability.

The medication is taken orally, usually with meals to minimise gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious adverse reaction is lactic acidosis, a rare but potentially fatal metabolic disturbance. Risk is higher in patients with severe renal or hepatic impairment, excessive alcohol intake, or conditions that predispose to hypoxia. Prompt medical attention is required if symptoms such as unexplained fatigue, rapid breathing or abdominal pain occur.

Metformina Pharmconsul is contraindicated in patients with known hypersensitivity to metformin, severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in those with significant hepatic disease. It should also be avoided in individuals with conditions that increase the risk of lactic acidosis.